URGENT: Class Action Filed for Securities Fraud Against UroGen Pharma Ltd.

UroGen Pharma Ltd. is currently facing a securities fraud class action lawsuit filed by Levi & Korsinsky. The deadline for investors to join the class action is set for July 28, 2025. The lawsuit alleges that UroGen Pharma Ltd. made misleading statements regarding the efficacy of its product, UGN-101, and failed to disclose certain information to investors.

UGN-101 is a treatment for low-grade upper tract urothelial cancer (LG UTUC). UroGen Pharma Ltd. claimed that the drug showed promising results in its Phase 3 OLYMPUS trial, leading investors to believe that the drug was on track for approval by the FDA. However, it was later revealed that the trial did not meet its primary endpoint, causing UroGen Pharma Ltd.’s stock price to plummet.

In addition to the misleading statements about UGN-101, the lawsuit also alleges that UroGen Pharma Ltd. failed to disclose important information about the OLYMPUS trial. This information included the fact that the trial had a high dropout rate and that the company had changed the statistical analysis plan after the trial had been unblinded.

Investors who purchased UroGen Pharma Ltd. securities between December 1, 2017, and December 11, 2019, are encouraged to join the class action lawsuit. By participating in the lawsuit, investors may be able to recover some of their losses incurred as a result of UroGen Pharma Ltd.’s alleged securities fraud.

If you are interested in joining the class action lawsuit against UroGen Pharma Ltd., you must do so before the July 28, 2025, deadline. Investors who wish to participate should contact Levi & Korsinsky as soon as possible to discuss their legal options.

It is essential for investors to hold companies accountable for their actions and to ensure that their rights are protected. By participating in the securities fraud class action lawsuit against UroGen Pharma Ltd., investors can seek justice for any losses they may have suffered as a result of the company’s alleged misconduct.